PYXS
Pyxis Oncology IncNASDAQ
Healthcare • Biotechnology
Factor tilt: Micro-Cap Growth
$1.66+3.11%
Close Nov 6, 2026
- Market cap
- $198.3M
- 1 month
- -16.6%
- 3 months
- -56.7%
- 1 year
- -57.5%
- 52-week range
- $1.06$5.34
- Dividend
- No dividends on record
- Next-quarter EPS estimate
- -$0.28Quarter to Sep 30, 2026 · 9 analysts · 0.0% in 30d
- Short interest
- 7.3% of float4.3M shares · settled Oct 15, 2026 · -11.1% since Sep 30, 2026 · FINRA
Fundamentals · trailing 12 months to Jun 30, 2026
- Revenue
- $11.04M
- Net income
- -$88.73M
- Free cash flow
- -$67.92M
- Book value
- $11.44M
- Total debt
- $17.83M
- P/E
- —
- Price / sales
- 18×
- Price / book
- 17.3×
- FCF yield
- -34.3%
- Net margin
- -803.8%
EODHD (TTM) · as of Nov 6, 2026
End-of-day close from stored market data, not a live quote.
About Pyxis Oncology Inc
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an
Read more
inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has an in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
- Website
- pyxisoncology.com
- Headquarters
- Boston, MA, United States
- Employees
- 56
- Listed
- Oct 8, 2021
- Fiscal year ends
- December
Company profile from EODHD, stored Oct 29, 2026.
Quarterly results
The last 8 fiscal quarters as reported (EODHD). Year over year compares the same quarter a year earlier.
| Quarter | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Jun 2026filed Aug 13, 2026 | — | — | — | -$26.0M | -$25.3M |
| Mar 2026filed May 14, 2026 | — | — | — | -$24.4M | -$23.3M |
| Dec 2025filed Mar 23, 2026 | $11.0M | +224.5% | — | -$18.3M | -$18.1M |
| Sep 2025filed Nov 3, 2025 | — | — | — | -$23.5M | -$22.0M |
| Jun 2025filed Aug 14, 2025 | $2.8M | — | — | -$19.8M | -$18.4M |
| Mar 2025filed May 15, 2025 | — | — | — | -$22.9M | -$21.2M |
| Dec 2024filed Mar 18, 2025 | $3.4M | -0.5% | 50.0% | -$40.1M | -$35.6M |
| Sep 2024filed Nov 12, 2024 | — | — | — | -$23.8M | -$21.2M |
Fiscal years · last 6
| Fiscal year | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Dec 2025filed Mar 23, 2026 | $13.9M | -14.2% | 82.8% | -$84.4M | -$79.6M |
| Dec 2024filed Mar 18, 2025 | $16.1M | — | 97.1% | -$89.5M | -$77.3M |
| Dec 2023filed Mar 21, 2024 | — | — | — | -$82.2M | -$73.8M |
| Dec 2022filed Mar 22, 2023 | — | — | — | -$123.5M | -$118.0M |
| Dec 2021filed Mar 29, 2022 | — | — | — | -$69.7M | -$76.0M |
| Dec 2020filed Dec 31, 2020 | — | — | — | -$12.9M | -$12.8M |
Short-interest history
FINRA reports open short positions for a settlement date. The publication date is later. These are reported positions, with a separate date for each observation.
Compare the reported short exposure around the dates you bought, sold or watched PYXS. A long position benefits from price rises; a short position benefits from falls. A change in these counts does not predict either move.
Settlement Oct 15, 2026
4,345,953 shares short
-540,699 shares (-11.1%) vs Sep 30, 2026
7.3% of the stored float. Published Oct 26, 2026.
Settlement Sep 30, 2026
4,886,652 shares short
+208,130 shares (+4.4%) vs Sep 15, 2026
9.9% of the stored float. Published Oct 9, 2026.
Settlement Sep 15, 2026
4,678,522 shares short
+710,417 shares (+17.9%) vs Aug 31, 2026
15.9% of the stored float. Published Sep 24, 2026.
Settlement Aug 31, 2026
3,968,105 shares short
-457,437 shares (-10.3%) vs Aug 14, 2026
13.5% of the stored float. Published Sep 10, 2026.
Settlement Aug 14, 2026
4,425,542 shares short
+253,388 shares (+6.1%) vs Jul 31, 2026
Share of float unavailable. Published Aug 25, 2026.
Settlement Jul 31, 2026
4,172,154 shares short
+918,501 shares (+28.2%) vs Jul 15, 2026
Share of float unavailable. Published Aug 11, 2026.
Change = this settlement’s shares short − the previous recorded settlement’s shares short; percentage change divides by that earlier count. A zero earlier count has no percentage change. Split-spanning counts are left uncompared. Float percentages use the stored settlement observation, not today’s float.
Source: stored FINRA equity short-interest records, up to six settlements from the last 240 days. FINRA data and reporting dates · How to read short interest
Dividends and stock splits
See the recorded cash amounts and dates behind PYXS’s income, and the splits that change its share count. Dates below are stored event records, not confirmation of a payment to your account.
Cash-dividend records
No qualified cash-dividend records are stored. This does not establish that the company pays no dividend.
Up to six Polygon cash-dividend events, including recorded ex-dates within the next 120 days. Amounts retain their recorded currency and decimal precision. Historical amounts are not restated to a common split basis, annualized, or converted to dollars.
For a long holding, compare the ex-date with when you held the shares and check the pay date against your broker’s cash history. Owning the stock today does not establish past entitlement. For a short holding, a dividend can create a payment obligation to the share lender.
Ex-dates and special dividend rules · Short-sale dividend obligations · Dividend data definitions
Split history
No qualified split events are stored. This does not establish that the stock has never split.
Up to six stored split dates through Nov 7, 2026. Equivalent vendor ratios are combined; conflicting ratios are left out. This history may be incomplete.
A split changes the share count and per-share price basis; it does not by itself add investment value. Put your holding’s earlier and later share counts on the same basis before comparing them. This applies to both long shares and shares owed on a short position.
How stock splits workPortfolio context
Sign in to see your position size
We’ll show you if PYXS is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
Smart money context
Holder IQ: HIGH
20 smart-money holders: institutions with a high Holder IQ
Q2 2026, filed Sep 22, 2026
Smart-money 13F trend: distributing (heavy)
Unlock crowding heatmapUnlock filer discoveryInsider context
Sentiment: bullish
Last trade: buy 29 days ago
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
Stored recent-activity label: bullish. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Red flags: 2
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
Stored recent-activity label: bullish. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Largest 13-F holders · Q2 2026
76 filers reported a long position in PYXS for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
The top 10 hold
84.7%
of the 34.2M shares 13-F filers reported
Moves vs Q1 2026
5 added4 trimmed
1 unchanged
Net shares held
+31.4%
across the 10 holders with a comparable Q1 2026 book
| Rank | Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|---|
| 1 | GordonMD Global Investments LP | $30.2M · 10M shares | 10M | +143.2% |
| 2 | PFIZER INC | $19.5M · 7M shares | 7M | Unchanged |
| 3 | Laurion Capital Management LP | $14.8M · 4.9M shares | 4.9M | -1.9% |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | $6.2M · 2.1M shares | 2.1M | +2.1% |
| 5 | Atle Fund Management AB | $2.9M · 966.5K shares | 966.5K | +390.5% |
| 6 | BlackRock, Inc. | $2.6M · 867.9K shares | 867.9K | +10% |
| 7 | Palo Alto Investors LP | $2.6M · 864.3K shares | 864.3K | -14.5% |
| 8 | MARSHALL WACE, LLP | $2.5M · 830.5K shares | 830.5K | +134.3% |
| 9 | RENAISSANCE TECHNOLOGIES LLC | $2.3M · 772.2K shares | 772.2K | -13.1% |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | $1.8M · 591.8K shares | 591.8K | -1% |
Sign in to see each holder’s Holder IQ, factor-adjusted Holder IQ and rank, and compare these holders with all scored filers. Available on every plan.
Sign in5% holder filings (13D / 13G)
Holders of more than 5% of PYXS file with the SEC within days. A 13D holder may seek to influence the company; a 13G holder is passive. Each holder’s latest filing from the last three years.
| Filed | Holder | % of class |
|---|---|---|
| Nov 3, 2026 | Laurion Capital Management LP13G · passive · amended | 5.16% |
| Oct 9, 2026 | GordonMD Global Investments LP13G · passive · amended | 16.4% |
| Oct 5, 2026 | Coastlands Capital LP13G · passive | 5.42% |
| Jul 10, 2026 | BIOTECHNOLOGY VALUE FUND L P13G · passive | 9.99% |
Get the Full Analysis for PYXS
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.